Company intelligence / Profile preview

ZZ Biotech

Houston, Texas, United Stateszzbiotech.com ↗

Ownership: Private
Development stage: Phase 3

Overview

ZZ Biotech's lead drug, "3K3A‑APC," a genetically engineered variant of human activated protein C, has shown promise in addressing unmet needs in acute ischemic stroke and received FDA Fast Track designation. The company also pursues programs for neurodegenerative diseases and chronic wound healing. Patent activity suggests additional work on monoclonal antibodies and anti-inflammatory agents. Clinical results indicate safety and potential efficacy in early trials.

Therapeutic areas: DermatologyCardiovascularNeurology
Modalities: biologics (genetically engineered proteins)monoclonal antibodies (patent topics)glucocorticoids (patent topics)serine protease variants
Industry: Biotech

Drug pipeline

1 asset

3K3A-APC

Partnerships

No major pharma partnerships disclosed; investor Broadview Ventures noted.

Beyond the preview

Go deeper on ZZ Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZZ Biotech.

Explore the full profile